— Know what they know.
Not Investment Advice

DECN OTC

Decision Diagnostics Corp.
1W: -99.0% 1M: -99.0% 3M: -99.0% YTD: -99.0% 1Y: -99.0% 3Y: -99.0% 5Y: -100.0%
$0.00
+0.00 (+0.00%)
 
Weekly Expected Move ±8124.6%
$-0 $-0 $0 $0 $0
OTC · Healthcare · Medical - Pharmaceuticals · Tech Score Neutral · Power 58 · $35787 mcap · 380M float · 0.439% daily turnover · Short 100% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range0.0001-0.000151
Volume2,000,000
Avg Volume1,668,833
Beta-0.05
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOKeith Berman
Employees6
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2002-02-08
2660 Townsgate Road
Westlake Village, CA 91361
US
805 446 1973
About Decision Diagnostics Corp.

Decision Diagnostics Corp. (DECN), founded in 2000 and based in Westlake Village, California, specializes in developing electronic medical record (EMR) technologies primarily optimized for smartphones. The company provides a wide array of offerings, including both regulated and unregulated diagnostic solutions, as well as home-use testing products for individuals managing chronic illnesses. They also facilitate direct-to-patient logistics for diabetes programs and concentrate on creating mobile-centric e-health products and associated technological innovations. A key part of their product line involves glucose monitoring. This includes the GenUltimate! glucose test strips, classified as a Class II medical device for personal at-home human use. For animal health, they manufacture PetSure! glucose test strips, designed to measure glucose levels in dogs and cats and compatible with legacy Zoetis AlphaTrak glucometers. Additionally, they offer the proprietary GenUltimate! 4Pets Glucose system, which combines the GenUltimate! 4Pets strip with the Avantage meter, enabling glucose testing for canine, feline, and equine patients. Further glucose strip options include GenUltimate! Sure and GenUltimate! Precis. Beyond product development, Decision Diagnostics actively acquires and maintains a portfolio of intellectual property, spanning patents, trademarks, and specialized manufacturing equipment. Their software solutions include MD@Hand, a comprehensive management system for both inpatient and outpatient care; Practice Probe, a data mining utility designed to extract information from physician practice management systems; and ResidenceWare, a residential management system that streamlines communication between commercial or residential real estate managers and their tenants through networked applications. Ultimately, their EMR innovations provide crucial tools for physicians directly at the point of patient care. The company was originally known as InstaCare Corp. before officially changing its name to Decision Diagnostics Corp. in November 2011.

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms